Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis
暂无分享,去创建一个
John W. Mellors | John M. Coffin | Sarah Palmer | Richard T. Davey | Julia A. Metcalf | S. Hammer | R. Dewar | J. Metcalf | R. Davey | J. Falloon | J. Mellors | J. Coffin | F. Maldarelli | S. Palmer | M. Kearney | Holly Z. Bazmi | Frank Maldarelli | Mary Kearney | Diane Rock | Judith Falloon | Holly Bazmi | Robin L. Dewar | Mary F. Kearney | Elias K. Halvas | Christian J. Bixby | Scott Hammer | E. Halvas | Christian Bixby | D. Rock | Diane Rock
[1] C. Charpentier,et al. Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease Inhibitors , 2004, Journal of Virology.
[2] R. Shafer,et al. Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group. , 1998, Journal of virological methods.
[3] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.
[4] L. Loeb,et al. Fidelity of HIV-1 reverse transcriptase. , 1988, Science.
[5] D. Richman,et al. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. , 1998, AIDS Research and Human Retroviruses.
[6] L. Bacheler,et al. Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy , 2000, Antimicrobial Agents and Chemotherapy.
[7] J. Margolick,et al. Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.
[8] J. Condra,et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.
[9] T. Merigan,et al. Human Immunodeficiency Virus Type 1 Protease Genotypes and In Vitro Protease Inhibitor Susceptibilities of Isolates from Individuals Who Were Switched to Other Protease Inhibitors after Long-Term Saquinavir Treatment , 1998, Journal of Virology.
[10] P. Simmonds,et al. Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates. , 1991, AIDS.
[11] J. Thompson,et al. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.
[12] L. M. Mansky,et al. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.
[13] K. Livak,et al. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. , 1995, PCR methods and applications.
[14] Tuofu Zhu,et al. Virus Population Homogenization following Acute Human Immunodeficiency Virus Type 1 Infection , 2002, Journal of Virology.
[15] E. Holmes,et al. Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[16] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.
[17] J. Heeney,et al. A strategy for cloning infectious molecular clones of retroviruses from serum or plasma. , 2000, Journal of virological methods.
[18] J. Mellors,et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.
[19] C. Kuiken,et al. HIV sequence databases. , 2003, AIDS reviews.
[20] K Bebenek,et al. The accuracy of reverse transcriptase from HIV-1. , 1988, Science.
[21] S. Hammer,et al. The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan , 2000, Antiviral therapy.
[22] L. P. Zhao,et al. HIV Quasispecies and Resampling , 1996, Science.
[23] T. Merigan,et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy , 2000 .
[24] S. Paul,et al. Hiv Resistance Testing , 2003 .
[25] D. Richman,et al. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients , 1996, Journal of virology.
[26] S. Hammer,et al. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. , 2004, The Journal of infectious diseases.
[27] Diana D. Huang,et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. , 2002, AIDS research and human retroviruses.
[28] T. Merigan,et al. Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients , 1998, Annals of Internal Medicine.
[29] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[30] B. Rewari,et al. Antiretroviral Therapy for HIV Infection , 2007 .
[31] P Balfe,et al. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1 , 1990 .
[32] M. Mouroux,et al. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. , 2001, AIDS.
[33] Victor DeGruttola,et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. , 2002, JAMA.
[34] H. Agut,et al. From RNA to quasispecies: a DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity. , 2003, Journal of virological methods.
[35] Gary Collins,et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. , 2003, The New England journal of medicine.
[36] A. Leigh Brown,et al. Independent evolution of the env and pol genes of HIV‐1 during zidovudine therapy , 1996, AIDS.
[37] S. Paul,et al. HIV resistance testing. A clinical tool. , 2003, New Jersey medicine : the journal of the Medical Society of New Jersey.
[38] K. Metzner,et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. , 2003, The Journal of infectious diseases.
[39] K. Hertogs,et al. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting , 2001 .
[40] J. Schapiro,et al. Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial , 1999, The Lancet.
[41] E. Domingo,et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy , 1995, Journal of virology.
[42] R Hoh,et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.
[43] Rodrigo Lopez,et al. Multiple sequence alignment with the Clustal series of programs , 2003, Nucleic Acids Res..
[44] R. Laufs,et al. Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[45] G. Learn,et al. Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. , 1998, Virology.
[46] Jacques Izopet,et al. Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy , 2001, Journal of Virology.
[47] L. Menéndez-Arias. Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases. , 2002, Progress in nucleic acid research and molecular biology.
[48] V. Pathak,et al. Retroviral mutation rates and reverse transcriptase fidelity. , 2003, Frontiers in bioscience : a journal and virtual library.
[49] J. Corbeil,et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.